A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes

Autor: Bailey, Neil, Pagel, John M., Bensinger, William, Hegerova, Livia, Mawad, Raya, Milder, Michael, Szeto, Jennie, Trinh, Ngan, Tsomo, Tenzin, Wisniewski, Paul, Zayas, Clarisse M., Patel, Krish
Zdroj: Blood; November 2018, Vol. 132 Issue: Supplement 1 p1715-1715, 1p
Abstrakt: Pagel: Pharmacyclics, an AbbVie Company: Consultancy; Gilead: Consultancy. Bensinger:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; amgen: Speakers Bureau; Takeda: Speakers Bureau; celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Mawad:Swedish Cancer Institute: Employment. Patel:Pharmacyclics/Janssen: Speakers Bureau; Sunesis Pharmaceuticals: Consultancy; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Genentech: Consultancy, Speakers Bureau; Celgene: Consultancy; Juno Therapeutics: Consultancy.
Databáze: Supplemental Index